See more : PT Selaras Citra Nusantara Perkasa Tbk (SCNP.JK) Income Statement Analysis – Financial Results
Complete financial analysis of Dicerna Pharmaceuticals, Inc. (DRNA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Dicerna Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Oriental Watch Holdings Limited (ORWHF) Income Statement Analysis – Financial Results
- China Catalyst Holding Co., Ltd. (688267.SS) Income Statement Analysis – Financial Results
- AmeraMex International, Inc. (AMMX) Income Statement Analysis – Financial Results
- Tassal Group Limited (TSLLF) Income Statement Analysis – Financial Results
- ERAMET S.A. (ERMAY) Income Statement Analysis – Financial Results
Dicerna Pharmaceuticals, Inc. (DRNA)
About Dicerna Pharmaceuticals, Inc.
Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare, cardiometabolic, viral, and chronic liver diseases; complement-mediated diseases; and neurodegenerative diseases and pain. Its principal development programs include nedosiran for the treatment of primary hyperoxaluria; RG6346 for the treatment of chronic hepatitis B virus infection; belcesiran for the treatment of deficiency-associated liver disease; and DCR-AUD for the treatment of alcohol use disorder. Dicerna Pharmaceuticals, Inc. has strategic collaborations with Novo Nordisk A/S, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts. As of December 27, 2021, Dicerna Pharmaceuticals, Inc. operates as a subsidiary of Novo Nordisk A/S.
| Metric | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 164.31M | 23.90M | 6.18M | 2.28M | 295.00K | 184.00K | 0.00 | 0.00 | 7.02M | 7.91M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 164.31M | 23.90M | 6.18M | 2.28M | 295.00K | 184.00K | 0.00 | 0.00 | 7.02M | 7.91M |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 100.00% | 100.00% |
| Research & Development | 205.38M | 109.34M | 45.71M | 36.98M | 41.69M | 43.97M | 29.45M | 11.56M | 11.57M | 10.71M |
| General & Administrative | 72.13M | 42.75M | 21.69M | 25.88M | 18.35M | 19.24M | 15.65M | 5.82M | 4.70M | 4.82M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 72.13M | 42.75M | 21.69M | 25.88M | 18.35M | 19.24M | 15.65M | 5.82M | 4.70M | 4.82M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 277.52M | 152.09M | 67.40M | 62.86M | 60.04M | 63.21M | 45.10M | 17.38M | 16.27M | 15.52M |
| Cost & Expenses | 277.52M | 152.09M | 67.40M | 62.86M | 60.04M | 63.21M | 45.10M | 17.38M | 16.27M | 15.52M |
| Interest Income | 6.01M | 7.54M | 2.10M | 539.00K | 235.00K | 188.00K | 63.00K | 4.00K | 2.00K | 3.00K |
| Interest Expense | 20.00K | 3.00K | 603.00K | 0.00 | 0.00 | 0.00 | 199.00K | 952.00K | 1.34M | 997.00K |
| Depreciation & Amortization | 2.22M | 1.25M | 774.00K | 778.00K | 840.00K | 727.00K | 848.00K | 523.00K | 551.00K | 474.00K |
| EBITDA | -110.51M | -119.20M | -87.48M | -59.27M | -58.67M | -62.11M | -46.89M | -17.04M | -8.23M | -7.09M |
| EBITDA Ratio | -67.26% | -498.67% | -1,416.39% | -2,602.99% | -19,889.15% | -33,756.52% | 0.00% | 0.00% | -117.29% | -89.59% |
| Operating Income | -113.21M | -128.19M | -61.22M | -60.59M | -59.75M | -63.03M | -45.10M | -17.38M | -9.25M | -7.61M |
| Operating Income Ratio | -68.90% | -536.25% | -991.26% | -2,660.83% | -20,253.56% | -34,253.80% | 0.00% | 0.00% | -131.86% | -96.27% |
| Total Other Income/Expenses | 461.00K | 7.73M | -27.63M | 539.00K | 235.00K | 188.00K | -2.84M | -1.14M | -871.00K | -943.00K |
| Income Before Tax | -112.75M | -120.46M | -88.85M | -60.05M | -59.51M | -62.84M | -47.94M | -18.52M | -10.12M | -8.56M |
| Income Before Tax Ratio | -68.62% | -503.93% | -1,438.68% | -2,637.15% | -20,173.90% | -34,151.63% | 0.00% | 0.00% | -144.28% | -108.19% |
| Income Tax Expense | 481.00K | 7.73M | -27.03M | 539.00K | 235.00K | 188.00K | -2.64M | -188.00K | 471.00K | 54.00K |
| Net Income | -112.75M | -120.46M | -88.85M | -60.05M | -59.51M | -62.84M | -47.94M | -18.52M | -10.12M | -8.56M |
| Net Income Ratio | -68.62% | -503.93% | -1,438.68% | -2,637.15% | -20,173.90% | -34,151.63% | 0.00% | 0.00% | -144.28% | -108.19% |
| EPS | -1.51 | -1.76 | -1.60 | -2.90 | -2.87 | -3.09 | -2.98 | -1.11 | -4.95 | -0.11 |
| EPS Diluted | -1.51 | -1.76 | -1.60 | -2.90 | -2.87 | -3.09 | -2.98 | -1.11 | -4.95 | -0.11 |
| Weighted Avg Shares Out | 74.52M | 68.43M | 55.62M | 20.72M | 20.72M | 20.32M | 16.07M | 16.63M | 2.05M | 77.91M |
| Weighted Avg Shares Out (Dil) | 74.52M | 68.43M | 55.62M | 20.72M | 20.72M | 20.32M | 16.07M | 16.63M | 2.05M | 77.91M |
Dicerna to Report Second Quarter 2021 Financial Results on Aug. 9, 2021
Dicerna to Report Second Quarter 2021 Financial Results on Aug. 9, 2021
Dicerna Announces FDA Clearance of Investigational New Drug (IND) Application for DCR-AUD for the Treatment of Alcohol Use Disorder
Dicerna Announces FDA Clearance of Investigational New Drug (IND) Application for DCR-AUD for the Treatment of Alcohol Use Disorder
Dicerna Announces Interim Results From Phase 1 Trial of Belcesiran for Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Dicerna Announces Interim Results From Phase 1 Trial of Belcesiran for Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
New Strong Sell Stocks for July 15th
Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dicerna Initiates Patient Dosing in ESTRELLA Phase 2 Clinical Trial of Belcesiran for the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Dicerna Initiates Patient Dosing in ESTRELLA Phase 2 Clinical Trial of Belcesiran for the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Source: https://incomestatements.info
Category: Stock Reports